Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK4 | O96013 | 4/20 | 0.51 |
| ▸ | JAK3 | P52333 | 13/20 | 0.51 |
| ▸ | BTK | Q06187 | 10/20 | 0.51 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.50 |
| ▸ | EML4 | Q9HC35 | 1/20 | 0.47 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.47 |
| ▸ | TTK | P33981 | 1/20 | 0.45 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14547762 | 0.82 | CYP1A2 (0.42) | PAK4JAK3BTKALKTTK | |
| SCHEMBL18984923 | 0.81 | BTK (0.70) | PAK4JAK3BTKIRAK4PTK2 | |
| SCHEMBL12085351 | 0.81 | PAK4 (0.58) | PAK4JAK3BTKIRAK4TTK | |
| SCHEMBL12085346 | 0.79 | SYK (0.60) | PAK4JAK3BTKIRAK4 | |
| SCHEMBL3280599 | 0.77 | PTK2 (0.57) | JAK3BTKTTKPTK2 | |
| SCHEMBL14547841 | 0.77 | PAK4 (0.56) | PAK4JAK3BTKIRAK4TTK | |
| SCHEMBL3283548 | 0.77 | LRRK2 (0.57) | PAK4JAK3BTKEML4ALK | |
| SCHEMBL12085405 | 0.77 | ULK1 (0.56) | PAK4JAK3BTKIRAK4 | |
| SCHEMBL12085274 | 0.76 | PAK4 (0.55) | PAK4JAK3BTKIRAK4TTK | |
| SCHEMBL18984872 | 0.76 | JAK3 (0.61) | PAK4JAK3BTKIRAK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007042299-A1 | PYRROLOPYRIMIDINE DERIVATIVES AS SYK INHIBITORS | GLAXO GROUP LIMITED (GB) | 2007-04-19 | — | — | WO | disclosed |